US FDA panel review set for Acusphere's imaging agent
This article was originally published in Scrip
Executive Summary
The US FDA's cardiovascular and renal drugs advisory panel will meet on December 10th to discuss Acusphere's cardiovascular ultrasound imaging agent Imagify (perflubutane polymer microspheres). The proposed use is for patients with stable chest pain being evaluated for inducible ischaemia for the detection of coronary artery disease based on assessment of myocardial perfusion and wall motion. Imagify is the first ultrasound imaging agent designed to assess blood flow in the heart and the first to demonstrate, in large clinical trials, clinically equivalent accuracy to nuclear stress testing, the current standard for assessing myocardial perfusion, Acusphere said. The company said its lead product candidate would present a lower cost, speedier and non-radioactive option to nuclear stress testing .The NDA is undergoing a standard review, and the user fee date is February 28th.
You may also be interested in...
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.
Eye On ODAC: Former Members, FDA’s Pazdur Talk Pre-Meeting Mindsets, Impact Of Sponsor’s Experts
Oncologic Drugs Advisory Committee reps and the Oncology Center of Excellence director go behind the scenes to discuss FDA interactions with panelists, how opinions can change during a meeting, and why the voting question is important.